Preliminary, Real-world, Multicenter Experience with Omadacycline for Mycobacterium abscessus Infections

Taylor Morrisette, Sara Alosaimy, Julie V. Philley, Carly Wadle, Catessa Howard, Andrew J. Webb, Michael P. Veve, Melissa L. Barger, Jeannette Bouchard, Tristan W. Gore, Abdalhamid M. Lagnf, Iman Ansari, Carlos Mejia-Chew, Keira A. Cohen, Michael J. Rybak

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for Mycobacterium abscessus. The majority of infections were of pulmonary origin (7/12; 58.3%). The median (interquartile range) duration of OMC was 6.2 (4.2-11.0) months. Clinical success occurred in 9/12 (75.0%) patients. Three patients experienced a possible adverse effect while on therapy.

Original languageEnglish
Article numberofab002
JournalOpen Forum Infectious Diseases
Volume8
Issue number2
DOIs
StatePublished - Feb 1 2021

Keywords

  • Mycobacterium abscessus
  • omadacycline
  • rapidly growing nontuberculous mycobacteria

Fingerprint

Dive into the research topics of 'Preliminary, Real-world, Multicenter Experience with Omadacycline for Mycobacterium abscessus Infections'. Together they form a unique fingerprint.

Cite this